Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cortes

Showing results (181-190 of 231) with videos related to

Pageof 24
Sort By:
Frontiers in Medicine|January 31, 2022
ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES StudyManuela Monti, Tom Degenhardt, Etienne Brain, et al.
The Lancet. Oncology|October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trialEdith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 12, 2023
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysisViola Salvestrini, Kyubo Kim, Saverio Caini, et al.
Breast Cancer Research and Treatment|July 7, 2017
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancerHope S Rugo, Olivier Trédan, Jungsil Ro, et al.
The Journal of Pathology. Clinical Research|April 17, 2024
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119Javier Cortes, Eric P Winer, Oleg Lipatov, et al.
European Journal of Cancer (Oxford, England : 1990)|November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 studyPeter Schmid, Oleg Lipatov, Seock-Ah Im, et al.
Melanoma Research|September 15, 2015
BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitorsMaria Gonzalez-Cao, Clara Mayo-de-Las-Casas, Miguel A Molina-Vila, et al.
Breast Cancer Research : BCR|November 12, 2020
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trialMiguel Quintela-Fandino, Esther Holgado, Luis Manso, et al.
NPJ Breast Cancer|June 8, 2021
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancersLeticia De Mattos-Arruda, Javier Cortes, Juan Blanco-Heredia, et al.
Pageof 24

Showing results (181-190 of 231) with videos related to

Sort By:
Pageof 24
Frontiers in Medicine|January 31, 2022
ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES StudyManuela Monti, Tom Degenhardt, Etienne Brain, et al.
The Lancet. Oncology|October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trialEdith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 12, 2023
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysisViola Salvestrini, Kyubo Kim, Saverio Caini, et al.
Breast Cancer Research and Treatment|July 7, 2017
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancerHope S Rugo, Olivier Trédan, Jungsil Ro, et al.
The Journal of Pathology. Clinical Research|April 17, 2024
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119Javier Cortes, Eric P Winer, Oleg Lipatov, et al.
European Journal of Cancer (Oxford, England : 1990)|November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 studyPeter Schmid, Oleg Lipatov, Seock-Ah Im, et al.
Melanoma Research|September 15, 2015
BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitorsMaria Gonzalez-Cao, Clara Mayo-de-Las-Casas, Miguel A Molina-Vila, et al.
Breast Cancer Research : BCR|November 12, 2020
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trialMiguel Quintela-Fandino, Esther Holgado, Luis Manso, et al.
NPJ Breast Cancer|June 8, 2021
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancersLeticia De Mattos-Arruda, Javier Cortes, Juan Blanco-Heredia, et al.
Pageof 24